Last reviewed · How we verify
torasemide-IR
Torasemide-IR, marketed by Ferrer Internacional S.A., is a diuretic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term revenue generation potential. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | torasemide-IR |
|---|---|
| Sponsor | Ferrer Internacional S.A. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (PHASE4)
- Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects (PHASE1)
- Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension. (PHASE4)
- Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- torasemide-IR CI brief — competitive landscape report
- torasemide-IR updates RSS · CI watch RSS
- Ferrer Internacional S.A. portfolio CI